ERACVV, or the European Risk Assessment Committee on Vaccination and Vaccine-preventable diseases, is responsible for evaluating and recommending vaccines to be used in Europe. One of their responsibilities is to select the appropriate type of vaccine for certain populations.
However, the selection of vaccine carries potential risks. In this article, we will explore whether eracvv.me selection of CC (COVID-19 vaccination with ChAdOx1-SARS-CoV-2) is worth the risk.
Understanding CC
CC is a type of COVID-19 vaccine developed by AstraZeneca in collaboration with the University of Oxford. It uses a different technology than the mRNA vaccines made by Pfizer-Biotech and Modern. Instead, it employs a viral vector, which is a harmless virus that has been modified to carry the genetic instructions for making the spike protein of the SARS-CoV-2 virus.
Once injected into the body, the viral vector delivers the genetic material to cells, which then produce the spike protein. The immune system recognizes the protein as foreign and mounts an immune response against it. If the person later becomes infected with SARS-CoV-2, the immune system will recognize and attack the virus.
ERACVV’s Selection of CC
In February 2021, ERACVV recommended the use of CC for people aged 18 and above, including those over 65 years old. However, in March 2021, several European countries suspended the use of CC due to reports of blood clotting disorders among a small number of recipients.
After conducting a review of the available data, ERACVV concluded that the benefits of CC outweigh the risks and recommended its continued use. The committee also recommended that healthcare professionals and recipients should be made aware of the possible side effects and how to identify them.
Risks Associated with CC
The main risk associated with CC is the development of blood clots, particularly cerebral venous sinus thrombosis (CVST), a type of blood clot that forms in the brain. According to ERACVV, the risk of developing CVST after receiving CC is very low, estimated at about 1 case per 100,000 vaccinated people.
Other reported side effects include headache, fatigue, muscle pain, and fever, which are common after vaccination and usually resolve within a few days. However, some recipients may experience more severe allergic reactions or anaphylaxis, although these are erratichour.
Is the Risk Worth it?
The decision to receive CC should be based on an individual’s personal risk-benefit analysis. For most people, the benefits of getting vaccinated against COVID-19 far outweigh the risks associated with CC.
COVID-19 is a highly infectious disease that has caused millions of deaths worldwide. The development of vaccines has been a critical tool in controlling the spread of the virus and preventing severe illness and death.
CC has been shown to be effective in preventing COVID-19, including severe disease and hospitalization. It also provides protection against new variants of the virus, which have emerged globally.
Moreover, the risk of developing serious side effects from CC is very low. According to data from the European Medicines Agency (EMA), as of April 4, 2021, there had been 222 cases of CVST reported among around 34 million people who had received CC in the European Economic Area (EEA). This translates to a rate of approximately 1 case per 153,000 vaccinations.
Conclusion
ERACVV’s selection of CC as a COVID-19 vaccine has been controversial due to reports of blood clotting disorders among recipients. However, after conducting a thorough review of the available data, the committee concluded that the benefits of CC outweigh the risks and recommended its continued use.
While there is a small risk of developing blood clots after receiving CC, the benefits of being vaccinated against COVID-19 far outweigh this risk. The vaccine has been shown to be effective in preventing severe illness and death from the virus, which has caused millions of deaths worldwide.
Individuals should weigh the risks and benefits of CC based on their personal circumstances and consult with their healthcare provider if they have any concerns. However, for most people, the benefits of getting vaccinated with CC far outweigh the risks.
